SEER
Seer, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.95
+0.52%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 13.8M | 16.1M | 13.9M | 15.2M | 14.7M |
| Cost of Revenue | 7.4M | 8.1M | 7.1M | 13.7M | 14.3M |
| Gross Profit | 6.4M | 8.0M | 6.8M | 1.4M | 384.0K |
| Operating Expenses | |||||
| R&D Expense | 37.6M | 43.9M | 50.6M | 47.4M | 45.8M |
| SG&A Expense | 40.1M | 42.6M | 56.6M | 59.0M | 52.6M |
| General & Admin Expense | 10.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (367.0K) | (459.0K) | (223.0K) | — | — |
| Total Operating Expenses | 77.2M | 86.0M | 106.9M | 106.4M | 98.4M |
| Cost and Expenses | 84.7M | 94.1M | 114.0M | 120.1M | 112.7M |
| Operating Income (EBIT) | (70.8M) | (78.0M) | (100.1M) | (104.9M) | (98.0M) |
| Non-Operating | |||||
| Interest Income | 9.6M | 11.5M | 16.7M | 17.8M | 4.6M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 9.6M | 11.5M | 16.7M | 17.8M | 4.6M |
| Other Non-Op Income/Expense | 2.9M | 4.6M | 13.6M | 18.7M | 5.1M |
| Non-Operating Income (excl Interest) | (2.1M) | — | (13.6M) | (18.7M) | (5.1M) |
| EBT (Pre-Tax Income) | (67.9M) | (73.4M) | (86.5M) | (86.3M) | (93.0M) |
| Income Tax Expense | 71.0K | 201.0K | 98.0K | — | — |
| Bottom Line | |||||
| Net Income | (68.0M) | (73.6M) | (86.6M) | (86.3M) | (93.0M) |
| Earnings from Cont. Ops | (68.0M) | (73.6M) | (86.6M) | (86.3M) | (93.0M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (68.0M) | (73.6M) | (86.6M) | (86.3M) | (93.0M) |
| Per Share | |||||
| Basic EPS | ($1.22) | ($1.28) | ($1.39) | ($1.35) | ($1.42) |
| Diluted EPS | ($1.22) | ($1.28) | ($1.39) | ($1.35) | ($1.42) |
| Revenue Per Share | $0.25 | $0.28 | $0.22 | $0.24 | $0.24 |
| Shares | |||||
| Basic Shares Outstanding | 55.2M | 57.4M | 62.3M | 63.9M | 62.4M |
| Diluted Shares Outstanding | 55.2M | 57.4M | 62.3M | 63.9M | 62.4M |
| Profitability Metrics | |||||
| EBITDA | (64.2M) | (71.9M) | (80.3M) | (80.7M) | (87.1M) |
| D&A | 4.5M | 6.1M | 6.2M | 5.6M | 5.9M |
| EBIT | (68.7M) | (78.0M) | (86.5M) | (86.3M) | (93.0M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026